PCOS Renamed to PMOS: Why the Change Matters for Diagnosis and Care
- A long-standing medical designation has been officially changed in a move that researchers say will transform the diagnosis, care, and awareness for approximately 170 million women worldwide.
- The shift in terminology is designed to more accurately reflect the nature of the condition.
- The effort to rename the condition was led by Professor Helena Teede, an endocrinologist at Monash Health and the director of Monash University’s Monash Centre for Health Research...
A long-standing medical designation has been officially changed in a move that researchers say will transform the diagnosis, care, and awareness for approximately 170 million women worldwide. The condition previously known as Polycystic Ovary Syndrome, or PCOS, has been renamed Polyendocrine Metabolic Ovarian Syndrome, or PMOS.
The shift in terminology is designed to more accurately reflect the nature of the condition. Doctors now describe it as a complex, multisystem hormonal and metabolic disorder rather than a disease defined by the presence of ovarian cysts.
The effort to rename the condition was led by Professor Helena Teede, an endocrinologist at Monash Health and the director of Monash University’s Monash Centre for Health Research & Implementation.
The Reasoning Behind the Name Change
Researchers argued that the PCOS label was medically misleading because the condition does not actually involve an increase in pathological ovarian cysts. The previous name failed to account for the wide array of psychological, dermatological, metabolic, and endocrine symptoms that patients experience.
This narrow clinical focus on the ovaries has contributed to significant gaps in care. According to the study, as many as 70 percent of people affected by the condition remain undiagnosed.
“What we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated. It was heartbreaking to see the delayed diagnosis, limited awareness and inadequate care afforded those affected by this neglected condition. While international guidelines have advanced awareness and care, a name change was the next critical step towards recognition and improvement in the long-term impacts of this condition.” Helena Teede, per Endocrine Society
Defining Polyendocrine Metabolic Ovarian Syndrome
PMOS is characterized as a hormonal imbalance where the ovaries produce excess androgens, which in turn disrupts reproductive hormones. This imbalance frequently leads to unpredictable ovulation, missed periods, and irregular menstrual cycles.
While ultrasound imaging may show small follicle cysts—fluid-filled sacs containing immature eggs—these are the result of a lack of ovulation rather than pathological cysts. Crucially, the presence of these cysts is not a requirement for a diagnosis.
The new name emphasizes the endocrine and metabolic dimensions of the disorder. Researchers describe PMOS as a multisystem condition driven by the combined interaction of ovarian hormones, androgens, neuroendocrine hormones, and insulin.
Broad Symptoms and Long-Term Health Impacts
A primary driver for the rename was the fact that the old label obscured the extent to which the condition affects the entire body. The study highlights that PMOS impacts multiple major bodily systems, leading to significant economic and health consequences over the long term.
The symptoms of PMOS are categorized across four primary areas:
- Metabolic: Including insulin resistance, obesity, type 2 diabetes, high blood pressure, fatty liver disease, cardiovascular disease, abnormal cholesterol, and sleep apnea.
- Reproductive: Including infertility, irregular menstrual cycles, pregnancy complications, and an increased risk of endometrial cancer.
- Psychological: Including anxiety, depression, eating disorders, and a general reduction in quality of life.
- Dermatological: Including acne, excess facial or body hair, and hair thinning.
The study notes that the previous term, PCOS, failed to capture this broad clinical picture, which contributed to patient dissatisfaction and widespread knowledge gaps among healthcare providers.
Diagnostic Standards and Global Consensus
Diagnosis of PMOS occurs only after other potential disorders have been ruled out. For adults aged 20 and older, clinicians use a specific set of worldwide standards. A diagnosis requires the presence of at least two of the following three criteria:
- Elevated androgen levels or clinical symptoms of excess androgens (hyperandrogenism).
- Irregular or absent ovulation (oligo-anovulation).
- Elevated anti-Müllerian hormone (AMH) levels or the presence of polycystic ovaries on an ultrasound.
The decision to change the name was the result of an extensive global consultation process. Researchers engaged 56 scientific, medical, and patient advocacy organizations to determine if a rename was justified.
This process involved workshops, implementation analyses, iterative surveys, and modified Delphi consensus methods. In total, feedback was collected from more than 14,000 health professionals and patients across the globe. The findings of this study were published in the journal The Lancet.
For the 170 million women of reproductive age living with the condition, the transition to the name PMOS is intended to be more than a semantic shift. Teede and her colleagues argue that the change will help expand research funding, accelerate the speed of diagnosis, and improve the way physicians communicate with patients about the systemic nature of the disorder.